Benjamin Miller
@BenMillerise • 11,382 subscribers
@Fundrise, $VCX, Co-Founder and CEO. Disclosures: https://t.co/JSVDJ9W7Wd https://t.co/qkf3tWylUQ https://t.co/8lYnOMEceQ
Videos
In 2011, I pitched a top securities attorney in New York on democratizing investing. After hearing me list all of the ways I believed retail investors were disadvantaged by the financial system, he just looked at me and said: “Why would you bother with the little guy?” Today, 15 later, we’re listing the Fundrise Innovation Fund on the NYSE under the ticker $VCX. The financial system has a structural problem that most people can feel but few can name. The most valuable private technology companies are worth hundreds of billions, even over a trillion dollars, and they’ve never gone public. The wealth creation that used to flow through public markets—enabling everyone to participate—now happens behind a wall that excludes everyday investors. AI compounds the urgency. The companies building the most transformative technology in a generation are growing at rates we’ve never seen before, and the gap between who owns that growth and who benefits from it widens every quarter. We started working on the Fundrise Innovation Fund in 2021 to test whether a public venture capital fund could work. Over 100,000 investors now own a portfolio concentrated in the leading private AI and technology companies, making VCX one of the largest funds of its kind to ever list on a major exchange. No accredited investor requirement. Now available in any brokerage account. When that attorney asked me why I’d bother with the little guy, I told him: because they’re getting screwed! But I believe today marks another step in building a better financial system for the individual investor. Onward
Benjamin Miller36,104 次观看 • 6 个月前
NEW Exclusive Interview: This miracle pill could make dogs live longer, with Celine Halioua, Founder & CEO of Loyal Celine Halioua is building the first drug ever FDA-approved for lifespan extension itself — starting with dogs. We sat down on Onward to talk about why she thinks longevity is the most under-built frontier in medicine and what’s next for Loyal. We cover: Why the U.S. healthcare system structurally can't build preventative medicine The "micro single-payer" reason dogs are the perfect first market "Save the dogs, save the world" — Loyal's Tesla-style master plan The September 2019 FDA pathway change that made the entire company possible Why big dogs die young (growth hormones that never turn off) Caloric restriction mimetics — the second drug, for dogs of any size Why drug development is mostly logistics and economics, not science Scenario planning the next five years of biotech Why Loyal is AI-resistant and AI-amplified Being fired (and rehired) from the longevity fund — twice Bottom 10% of her high school class → Oxford → dropping out six months from her PhD Watch the full episode below → 𝐓𝐈𝐌𝐄𝐒𝐓𝐀𝐌𝐏𝐒 (00:00) Celine Halioua, Founder & CEO of Loyal (01:36) What is Loyal? (02:29) Why big dogs die younger (05:47) How the second drug works (08:22) First longevity drug in history (09:37) Why longevity drugs never existed (16:13) The master plan (18:23) Private vs Public (20:00) Three steps to market (25:55) The regulatory loophole (29:27) Scenario planning (31:54) AI and drug development (35:42) Good scenario (38:03) Bad scenario (39:35) Unexpected scenario (44:06) Why Fundrise (49:27) Founding story
Benjamin Miller12,950 次观看 • 3 个月前
Most Americans make their biggest financial decision — buying a home — with less data than they'd use to buy a used car. RealAI just changed that. Institutional investors have always had access to professional financial analysis (comparable sales, forward forecasts, market analyses)...but it cost +$50K per property and took weeks. Now RealAI delivers it instantly, for free, to anyone.
Benjamin Miller17,779 次观看 • 7 个月前
没有更多内容可加载